<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03606070</url>
  </required_header>
  <id_info>
    <org_study_id>2016-A02074-47</org_study_id>
    <secondary_id>2016/2499</secondary_id>
    <nct_id>NCT03606070</nct_id>
  </id_info>
  <brief_title>Multiparametric PET-MRI Integration for a New Approach to Tumor Heterogeneity in Non-Small Cell Lung Cancer (NSCLC): Pilot Study</brief_title>
  <acronym>IMAHTEP</acronym>
  <official_title>Multiparametric PET-MRI Integration for a New Approach to Tumor Heterogeneity in Non-Small Cell Lung Cancer (NSCLC): Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gustave Roussy, Cancer Campus, Grand Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gustave Roussy, Cancer Campus, Grand Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To estimate the intra and inter-operator reproducibility of multiparametric regional PET-MRI
      mapping in locally advanced and trace mestastatic non-small cell lung cancer (NSCLC).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 25, 2017</start_date>
  <completion_date type="Anticipated">November 2020</completion_date>
  <primary_completion_date type="Anticipated">May 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Measurement of intra and inter-operator reproducibility of multiparametric regional PET-MRI mapping performed before and under treatment.</measure>
    <time_frame>Up to 24 months</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>NSCLC</condition>
  <arm_group>
    <arm_group_label>Patients with NSCLC</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Characterization of tumor heterogeneity by multiparametric regional mapping PET-MRI.
Patients will realize:
a PET-MRI examination performed before the chemoradiotherapy treatment (so-called baseline PET-MRI)
a PET-MRI examination performed midway through treatment (PET-MRI1 under treatment), after receiving 33 ± 4 Gy (approximately 2.5 months after the first PET-MRI).</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>PET-MRI</intervention_name>
    <description>a PET-MRI examination performed before the chemoradiotherapy treatment (so-called baseline PET-MRI)
a PET-MRI examination performed midway through treatment (PET-MRI1 under treatment), after receiving 33 ± 4 Gy (approximately 2.5 months after the first PET-MRI).</description>
    <arm_group_label>Patients with NSCLC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Locally advanced NSCLC (stages IIB, IIIA or IIIB of the TNM classification 7th
             edition) or trace metastatic stage IV (&lt;/=5 mestastasis, &lt;/= 3 organ reached)

          2. Exclusive therapeutic management by concomitant radio-chemotherapy administered in
             accordance with international recommendations (dual therapy with platinum salts)

          3. Signed consent

          4. Patients affiliated with the social security scheme or beneficiary of a similar
             scheme.

        Exclusion Criteria:

          1. Minor

          2. Pregnant / lactating woman

          3. Person deprived of liberty by judicial or administrative decision, adults who are the
             subject of a legal protection measure or unable to express their consent

          4. Previous cancer in the 2 years prior to registration

          5. Previousradiotherapy / thoracic surgery

          6. Patients under experimental treatment or for whom the administration of an
             experimental treatment is planned

          7. Claustrophobic patients

          8. Severe Renal Insufficiency (Clearance MDRD Cockroft &lt;30ml / min)

          9. Uncontrolled diabetes, hyperglycemia&gt; 1.8g / L

         10. Patient with metallic implants not compatible with MRI or any immovable implanted
             electronic medical device (eg pacemaker, neurostimulator, cochlear implants, etc.)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Caroline CARAMELLA, MD</last_name>
    <phone>0142114211</phone>
    <phone_ext>+33</phone_ext>
    <email>caroline.caramella@gustaveroussy.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <state>Val De Marne</state>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Caroline CARAMELLA, MD</last_name>
      <phone>0142114211</phone>
      <email>caroline.caramella@gustaveroussy.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>July 20, 2018</study_first_submitted>
  <study_first_submitted_qc>July 20, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 30, 2018</study_first_posted>
  <last_update_submitted>January 2, 2019</last_update_submitted>
  <last_update_submitted_qc>January 2, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 4, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

